Merck (UKEX:MRK) Cyclically Adjusted FCF per Share: ₴186.45 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UKEX:MRK Merck & Co Inc UKEX:MRK
72 GF Score
Price ₴4,844.00
GF Value ₴4,423.59
! 8 Warning Signs
View Full Analysis

What is Merck Cyclically Adjusted FCF per Share?

Merck UKEX:MRK 72 Cyclically Adjusted FCF per Share is ₴186.45 as of Mar. 2026. GuruFocus rates UKEX:MRK with a GF Score™ of 72/100 and a GF Value™ of ₴4,423.59. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Merck's adjusted free cash flow per share for the three months ended in Mar. 2026 was ₴52.690. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ₴186.45 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Merck's average Cyclically Adjusted FCF Growth Rate was 4.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 5.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 7.70% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 5.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Merck was 15.30% per year. The lowest was -3.70% per year. And the median was 5.30% per year.

As of today (2026-08-01), Merck's current stock price is ₴4844.00. Merck's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was ₴186.45. Merck's Cyclically Adjusted Price-to-FCF of today is 25.98.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Merck was 34.10. The lowest was 17.07. And the median was 24.04.


Merck  (UKEX:MRK) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Merck's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=4844.00/186.45
=25.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Merck was 34.10. The lowest was 17.07. And the median was 24.04.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Merck Cyclically Adjusted FCF per Share Related Terms


Merck Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Merck's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck Cyclically Adjusted FCF per Share Chart

Merck Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 131.59 135.32 216.68 208.01

Merck Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 240.15 274.14 267.80 208.01 186.45

UKEX:MRK vs AMGN, ABBV, GILD: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted Price-to-FCF falls into.


UKEX:MRK
72GF Score
Merck & Co Inc UKEX:MRK
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Merck's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=52.69/330.2130*330.2130
=52.690

Current CPI (Mar. 2026) = 330.2130.

Merck Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 19.545 241.018 26.778
201609 40.921 241.428 55.970
201612 49.406 241.432 67.574
201703 -0.853 243.801 -1.155
201706 47.280 244.955 63.736
201709 -26.305 246.819 -35.193
201712 53.855 246.524 72.137
201803 11.576 249.554 15.318
201806 46.199 251.989 60.540
201809 35.559 252.439 46.514
201812 44.989 251.233 59.132
201903 12.668 254.202 16.456
201906 39.582 256.143 51.028
201909 56.524 256.759 72.694
201912 65.401 256.974 84.041
202003 -4.874 258.115 -6.235
202006 49.132 257.797 62.933
202009 12.764 260.280 16.193
202012 45.095 260.474 57.169
202103 12.416 264.877 15.479
202106 26.349 271.696 32.024
202109 63.608 274.310 76.571
202112 67.109 278.802 79.484
202203 66.249 287.504 76.090
202206 55.589 296.311 61.949
202209 78.355 296.808 87.174
202212 57.300 296.797 63.751
202303 5.791 301.836 6.335
202306 48.004 305.109 51.954
202309 119.113 307.789 127.791
202312 -13.012 306.746 -14.007
202403 38.989 312.332 41.221
202406 84.765 314.175 89.092
202409 148.996 315.301 156.043
202412 44.113 315.605 46.155
202503 20.606 319.799 21.277
202506 44.782 322.561 45.844
202509 121.758 324.800 123.787
202512 32.649 324.054 33.270
202603 52.690 330.213 52.690

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ₴186.45 mean?
Merck (UKEX:MRK) has a Cyclically Adjusted FCF per Share of ₴186.45 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Merck and its competitors.
Is Merck's Cyclically Adjusted FCF per Share too high?
Merck's current Cyclically Adjusted FCF per Share is ₴186.45. Overall, Merck has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Merck's Cyclically Adjusted FCF per Share compare to AMGN and ABBV?
Merck's Cyclically Adjusted FCF per Share of ₴186.45 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Merck and its competitors. Merck's current Cyclically Adjusted FCF per Share is ₴186.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Merck (UKEX:MRK) has a current Cyclically Adjusted FCF per Share of ₴186.45. The stock's GF Value™ is ₴4,423.59, compared to a current price of ₴4,844.00 — trading 9.5% above its estimated fair value. The current Cyclically Adjusted FCF per Share is ₴186.45. Merck's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Merck (UKEX:MRK), the current Cyclically Adjusted FCF per Share is ₴186.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck (UKEX:MRK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck stock appears to be overvalued. The current stock price of ₴4,844.00 is trading 9.5% above its estimated GF Value™ of ₴4,423.59.

Key valuation signals for UKEX:MRK:

  • Cyclically Adjusted FCF per Share: ₴186.45
  • GF Value™: ₴4,423.59 vs. price of ₴4,844.00 (9.5% above fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the UKEX:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck Business Description

Address 126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
72GF Score

Get the complete analysis for UKEX:MRK

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₴4,844.00
Price
₴4,423.59
GF Value